Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 10 - 19 save search
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
Published: 2021-10-19 (Crawled : 21:00) - biospace.com/
AKRO | $21.8 0.37% 0.37% 940K
|
Health Technology
|
| O: -4.61%
H: 5.52%
C: 4.79%
treatment fda fda fast track fast track nash efruxifermin fast track designation designation
Covid News Brief: Vaccine Boosters, Profits, Treatment Updates and More
Published: 2021-10-19 (Crawled : 17:00) - biospace.com/
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: 0.49%
H: 2.64%
C: 1.85%
covid treatment vaccine
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
Published: 2021-10-19 (Crawled : 15:00) - biospace.com/
CYTH | $1.24 -1.61% 67K
|
Professional, Scientific, and T...
|
| O: -0.13%
H: 3.78%
C: 0.44%
disease treatment ema research
First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis
Published: 2021-10-19 (Crawled : 15:00) - biospace.com/
FWBI | $3.0 -8.26% -9.0% 62K
|
Manufacturing
|
| O: 6.23%
H: 1.38%
C: -3.1%
fda clearance treatment fda phase 2 biopharma application trial clearance phase 2b
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published: 2021-10-19 (Crawled : 13:00) - prnewswire.com
MBRX | $4.355 -2.35% -2.41% 16K
|
Health Technology
|
| O: 0.37%
H: 3.72%
C: 2.23%
covid treatment phase 1 trial phase 1b
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2021-10-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.445 -4.86% -5.11% 33K
|
Health Technology
|
| O: -0.88%
H: 4.42%
C: -1.77%
treatment atopic dermatitis dermatitis trial enroll
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
Published: 2021-10-19 (Crawled : 13:00) - biospace.com/
VRTX | $394.17 -0.8% -0.82% 690K
|
Health Technology
|
| O: 0.7%
H: 1.94%
C: 1.84%
treatment fibrosis conference cystic fibrosis
Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
Published: 2021-10-19 (Crawled : 12:00) - biospace.com/
ENTA 4 | $15.38 -4.77% -5.01% 210K
|
Health Technology
|
| O: 0.31%
H: 1.44%
C: 1.17%
covid treatment conference designation
Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases
Published: 2021-10-19 (Crawled : 12:00) - globenewswire.com
PSTV | $1.74 -3.33% 7.1K
|
Health Technology
|
| O: 4.68%
H: 0.0%
C: -1.96%
new drug fda clearance treatment fda application drug clearance
Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab
Published: 2021-10-19 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.16%
H: 4.62%
C: 4.46%
presentation treatment lenzilumab biomarkers
ChartWater™ backs researchers developing new treatment processes and applications at IHE Delft Institute for Water Education
Published: 2021-10-19 (Crawled : 11:00) - globenewswire.com
GTLS | $148.16 -1.29% 0.0% 510K
|
Producer Manufacturing
|
| O: 0.26%
H: 1.76%
C: 0.05%
education treatment application research
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.